Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan/Paclitaxel Induction and Consolidation Chemoradiotherapy in Limited Stage SCLC
NCT00003812Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 1999
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan and paclitaxel in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoints: Complete Response Rate up to 5 years and Overall Survival up to 5 years. Started Mar 1999; status: completed.
02
Drugs
topotecanpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003812.